AbbVie Inc. $ABBV Position Boosted by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. increased its position in AbbVie Inc. (NYSE:ABBV) by 6.2% in the third quarter, Holdings Channel.com reports. The firm owned 197,798 shares of the company’s stock after acquiring an additional 11,548 shares during the period. Factory Mutual Insurance Co.’s holdings in AbbVie were worth $51,742,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABBV. CrossGen Wealth LLC boosted its stake in AbbVie by 9.0% in the third quarter. CrossGen Wealth LLC now owns 6,519 shares of the company’s stock valued at $1,705,000 after acquiring an additional 536 shares during the last quarter. VCI Wealth Management LLC grew its holdings in AbbVie by 36.9% during the 3rd quarter. VCI Wealth Management LLC now owns 12,506 shares of the company’s stock worth $3,271,000 after acquiring an additional 3,370 shares during the period. Garde Capital Inc. grew its holdings in AbbVie by 58.7% during the 3rd quarter. Garde Capital Inc. now owns 2,354 shares of the company’s stock worth $616,000 after acquiring an additional 871 shares during the period. Gerber Kawasaki Wealth & Investment Management raised its position in shares of AbbVie by 16.7% during the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 5,492 shares of the company’s stock valued at $1,437,000 after acquiring an additional 786 shares during the last quarter. Finally, GRIMES & Co WEALTH MANAGEMENT LLC raised its position in shares of AbbVie by 1.0% during the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 104,631 shares of the company’s stock valued at $27,371,000 after acquiring an additional 997 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 1.0%

Shares of AbbVie stock opened at $285.88 on Wednesday. The stock’s fifty day simple moving average is $270.23 and its 200 day simple moving average is $237.89. The company has a market capitalization of $505.09 billion, a PE ratio of 49.20, a PEG ratio of 1.31 and a beta of 0.20. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $298.74.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The firm had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same period in the previous year, the firm earned $1.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. Analysts predict that AbbVie Inc. will post 14.00 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

Analyst Ratings Changes

ABBV has been the topic of a number of analyst reports. Leerink Partners increased their price target on AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research note on Monday. Royal Bank Of Canada lifted their price objective on AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. JPMorgan Chase & Co. increased their target price on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, Canaccord Genuity Group raised their target price on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $296.88.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.